Piramal Pharma Limited (PPL) has achieved a score of 63 on the 2025 S&P Global Corporate Sustainability Assessment (CSA), reflecting a significant 15% improvement over the previous year. This score places the company in the 91st percentile within the pharmaceutical industry. The CSA is a rigorous annual evaluation that assesses the sustainability practices of thousands of companies, focusing on environmental, social, and governance (ESG) performance.
PPL’s notable increase from last year’s score of 55 highlights the company’s ongoing commitment to sustainability and responsible operations. The S&P Global CSA is widely regarded as one of the most respected global sustainability benchmarking frameworks, providing organizations with valuable insights into their performance and areas for potential growth.
Piramal Pharma’s Commitment to Sustainable Practices
Piramal Pharma’s achievement in the CSA underscores its dedication to sustainable practices across its operations. Central to this progress is the company’s four-pillared sustainability approach, which integrates ESG principles into every aspect of its business. These pillars focus on Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
By enhancing its performance in these critical areas, PPL demonstrates its commitment to operations that benefit partners, patients, and the environment. “Our progress on the S&P Global CSA underscores our unwavering dedication to responsible operations and sustainable growth,” said Peter DeYoung, CEO of Piramal Global Pharma. He emphasized the company’s focus on excellence as it continues to expand its operations globally.
In addition to improving its sustainability score, PPL aims to leverage the insights gained from the CSA to drive further enhancements in its sustainability efforts. This commitment positions the company as a leader in the pharmaceutical sector, driving positive change within the industry.
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) operates a diverse portfolio of differentiated products and services through its 17 global development and manufacturing facilities. The company distributes its products in over 100 countries. PPL encompasses several divisions, including Piramal Pharma Solutions (PPS), a prominent contract development and manufacturing organization; Piramal Critical Care (PCC), which specializes in complex hospital generics; and the Piramal Consumer Healthcare business, offering over-the-counter wellness products.
Additionally, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited—a joint venture with Abbvie—has emerged as a market leader in the ophthalmology therapy area within the Indian pharmaceutical market. PPL also holds a strategic minority investment in Yapan Bio Private Limited, which operates in the biologics and vaccine segments.
For more information about Piramal Pharma, visit their official website or LinkedIn page.
